SCM
Sio Capital Management Portfolio holdings
AUM
$249M
This Quarter Return
+1.37%
1 Year Return
+117.71%
3 Year Return
+238.99%
5 Year Return
+411.91%
10 Year Return
+912.87%
AUM
$451M
AUM Growth
+$451M
(+39%)
Cap. Flow
+$52.2M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
37.93%
Holding
109
New
31
Increased
24
Reduced
17
Closed
18
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$17M |
| 2 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$16M |
| 3 |
AMN Healthcare
AMN
|
$15.9M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$14.8M |
| 5 |
Cigna
CI
|
$13.8M |
Top Sells
| 1 |
Merck
MRK
|
$8.84M |
| 2 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$8.51M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$8.26M |
| 4 |
Eli Lilly
LLY
|
$7.54M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$7.25M |
Sector Composition
| 1 | Healthcare | 83.97% |
| 2 | Consumer Staples | 0.92% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MESO
101
Mesoblast
MESO
$1.65B
| – | – |
0
| – | – |
|
102
Seres Therapeutics
MCRB
$162M
| – | – |
0
| – | – |
|
|
103
Eli Lilly
LLY
$661B
| – | – |
-45,901
| Closed | -$7.54M |
|
104
Inogen
INGN
$213M
| – | – |
-54,000
| Closed | -$1.92M |
|
105
Immunovant
IMVT
$2.91B
| – | – |
-152,450
| Closed | -$3.71M |
|
106
CEL-SCI Corp
CVM
$81.4M
| – | – |
0
| – | – |
|
107
Corbus Pharmaceuticals
CRBP
$121M
| – | – |
0
| – | – |
|
108
Boston Scientific
BSX
$159B
| – | – |
-112,036
| Closed | -$3.93M |
|
109
Biogen
BIIB
$20.8B
| – | – |
-13,800
| Closed | -$3.69M |
|